Basis of Presentation (Narrative) (Details) shares in Millions	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	May. 31, 2014 USD ($)	Jan. 31, 2012 USD ($)	Jan. 31, 2010 right	Jun. 30, 2015 USD ($) drug storage_location	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) drug storage_location segment customer shares	Jun. 30, 2014 USD ($) shares	Dec. 31, 2014 USD ($) customer	Aug. 31, 2014 USD ($)	Jan. 31, 2011 USD ($)
Earnings (Loss) Per Share
Common shares excluded from computation | shares						3.5	0.4
Cash, Cash Equivalents and Short-term Investments
Maturity period of cash and cash equivalents, maximum						3 months
Maturity period of short term investments, minimum						3 months
Concentrations of Credit Risk
Product Shelf Life						5 years
Number of Storage Locations | storage_location				3		3
Accounts receivable				$ 5,532,000		$ 5,532,000		$ 12,634,000
Inventory, Net [Abstract]
Inventory write downs				0	$ 0	$ 0	$ 0
Allowance for Doubtful Accounts
Accounts receivable outstanding considered past due after period, minimum						30 days
Accounts receivable outstanding considered past due after period, maximum						90 days
Allowance for doubtful accounts				0		$ 0		0
Property and Equipment
Depreciation				100,000	100,000	$ 100,000	100,000
Goodwill and Other Identifiable Intangible Assets
Finite-lived intangible asset, useful life						20 years
Amortization expense				600,000	600,000	$ 1,200,000	1,200,000
Amortization Expense
Amortization expense 2015				2,400,000		2,400,000
Amortization expense 2016				2,400,000		2,400,000
Amortization expense 2017				2,400,000		2,400,000
Amortization expense 2018				2,400,000		2,400,000
Amortization expense 2019				$ 2,400,000		$ 2,400,000
Revenue Recognition
Period allowed for return of products, minimum						30 days
Period allowed for return of products, maximum						90 days
Restocking fee (percent)						20.00%
Discontinued Operations
Number of drugs included in product line | drug				4		4
Segment Reporting
Number of reportable segments | segment						2
Minimum
Revenue Recognition
Period when partenr sales reports are received after end of quarter						30 days
Maximum
Revenue Recognition
Period when partenr sales reports are received after end of quarter						60 days
Equipment | Minimum
Property and Equipment
Estimated useful life of assets						3 years
Equipment | Maximum
Property and Equipment
Estimated useful life of assets						10 years
Cydex Pharmaceuticals, Inc
Contingent Liabilities
Contingent liability										$ 17,600,000
Fair value of liability				$ 10,400,000		$ 10,400,000		11,500,000
Contingent liability change in amount				1,000,000	3,200,000	2,200,000	2,700,000
Cydex Pharmaceuticals, Inc | Guaranteed Payment
Contingent Liabilities
Purchase of commercial license rights		$ 4,300,000
Cydex Pharmaceuticals, Inc | Revenue Sharing
Contingent Liabilities
Purchase of commercial license rights					1,600,000	3,200,000
Metabasis Therapeutics
Contingent Liabilities
Fair value of liability				8,400,000		8,400,000		$ 3,700,000
Contingent liability change in amount				(6,400,000)	1,900,000	$ (5,300,000)	(500,000)
Number of contingent value rights | right			4
Number of contingent value rights per series of contingent value rights | right			1
Number of contingent value rights issued for each share | right			4
Contingent value rights, frequency of cash payment			6 months
Accounts Receivable | Customer Concentration Risk
Concentrations of Credit Risk
Concentration risk, number of customers | customer						1		2
Concentration risk, percentage of accounts receivable						88.00%		64.00%
Acquired In Process Research And Development
Acquired In-Process Research and Development
Impairment of in-process research and development				0	$ 0	$ 0	$ 0
Omthera Pharmaceuticals
Milestone Payments
Event-based payment	$ 1,000,000
Proceeds from Collaborators								$ 500,000
Milestone payment received						0		0
Collaborative Arrangement, Product | Omthera Pharmaceuticals
Milestone Payments
Event-based payment								400,000
2019 convertible senior notes
Convertible Debt
Principal amount outstanding				$ 245,000,000		$ 245,000,000		$ 245,000,000
2019 convertible senior notes | Senior Notes
Convertible Debt
Principal amount outstanding									$ 245,000,000.0
Interest rate									0.75%